Research has shown that it stimulates hair follicles, supports scalp health at the cellular level, and plays a meaningful role in the hair growth cycle
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
AOD 9604 peptide, also called the fat-burning peptide, is an anti-obesity drug (AOD) that can also be used for losing weight for non-obese patients
2020;41(11):868-81 Zhang Y, Cheng Y, Liu J, et al
Gebert, L
You also want to make sure youre eating enough fiber